Mylan has announced that it will invest up to $100 million annually over a five-year period to add a total of 500 new jobs to its work forces in Dublin and Galway, Ireland by 2016. The investment includes funding for R&D and manufacturing in solid dose and injectables in addition to the respiratory area. Mylan currently employs approximately 700 people in Ireland at … [Read more...] about Mylan expands respiratory capabilities in Ireland
Business
FivePrime to discover asthma/COPD compounds for GSK
Biologics discovery company Five Prime Therapeutics has announced a deal with GlaxoSmithKline giving GSK "exclusive access to FivePrime’s drug discovery platforms in up to six programs to identify first-in-class agents and new mechanisms relevant to refractory asthma and chronic obstructive pulmonary disease (COPD)." This is the second discovery deal between the two … [Read more...] about FivePrime to discover asthma/COPD compounds for GSK
MAP gets new patent for Levadex, schedules meeting with FDA
MAP Pharmaceuticals has announced that it has a meeting scheduled with the FDA during the second quarter of this year to discuss the complete response letter it received for its Levadex inhaled dihydroergotamine application. MAP President and CEO Timothy S. Nelson said, "We are pleased that the FDA has scheduled a meeting with us to discuss the issues contained in the … [Read more...] about MAP gets new patent for Levadex, schedules meeting with FDA
US company introduces OTC horseradish nasal spray
Over-the-counter drug manufacturer GSC Products has introduced a horseradish nasal spray marketed as "Sinus Plumber." The company also developed a capsaicin nasal spray called Sinus Buster that was acquired by Hi-Tech Pharmacal earlier this year and a caffeinated nasal spray called Turbo Snort. Sinus Plumber, which the company is marketing as a cure for allergy … [Read more...] about US company introduces OTC horseradish nasal spray
SkyePharma announces second inhaler study with Respivert
SkyePharma has signed an agreement with RespiVert for a feasibility study to develop an inhaled dry powder formulation for a RespiVert compound, the second DPI project that the two companies have worked on together. Both projects involve the devlopment of inhaled drugs for the treatment of COPD and asthma. SkyePharma CEO Peter Grant commented, “We are pleased that … [Read more...] about SkyePharma announces second inhaler study with Respivert
Winston gets grant for development of nasal spray for trigeminal neuralgia
The National Institutes of Health (NIH) has awarded Winston Pharmaceuticals a $375,000 Small Business Innovation Research (SBIR) grant to support Phase 1 development of its civamide nasal spray for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). Civamide is a proprietary TRPV-1 receptor modulator that previously received orphan drug … [Read more...] about Winston gets grant for development of nasal spray for trigeminal neuralgia
Merck issues statement on Nasonex patent trial
Merck has issued a statement saying that the company "firmly believes its patent for Nasonex nasal spray is valid and infringed and will vigorously defend its intellectual property rights in a bench trial against Apotex Inc. and Apotex Corp. that began in US federal court today." Merck is suing Apotex for infringing U.S. Patent No. 6,127,353, issued to Schering in … [Read more...] about Merck issues statement on Nasonex patent trial
Two inhalers finalists in the Medical Design Excellence Awards
Two dry powder inhalers have been named as finalists in the 2012 Medical Design Excellence Awards sponsored by Medical Device and Diagnostic Industry. Sun Pharmaceutical's Combitide Starhaler and Novartis's TOBI Podhaler with Pulmosphere technology are both nominated in the "General Hospital Devices and Therapetic Products" category. Cambridge Consultants received … [Read more...] about Two inhalers finalists in the Medical Design Excellence Awards
European rights to aclidinium bromide to Menarini, review period extended by the FDA
Almirall has licensed European rights to aclidinium bromide, both as a monotherapy and in combination with formoterol to Italian pharmaceutical company Menarini. The agreement covers most of the EU except for the UK, the Netherlands and the Nordic countries, plus several additional countries, including Russia and Turkey. Almirall CEO Eduardo Sanchiz explained, … [Read more...] about European rights to aclidinium bromide to Menarini, review period extended by the FDA
Bausch + Lomb to acquire ISTA Pharmaceuticals
After spurning repeated offers from Valeant, ISTA Pharmaceuticals has agreed to be acquired by Bausch + Lomb for $9.10 per share in cash, a total of about $500 million. Valeant had offered $7.50 per share. In addition to its eyecare products, ISTA has been developing two bepotastine nasal sprays for allergic rhinitis, one a single therapy product and the other a … [Read more...] about Bausch + Lomb to acquire ISTA Pharmaceuticals